Clinical trial Recruiting at 1 site Interventional Ages 18 to 65

Health App Recommendation Tool to help dementia caregivers find suitable health apps.

Official title: Evaluating the Effectiveness of the Health App Recommendation Tool

Run by University of Pittsburgh · NCT07216716 · Data updated 2026-11-12

This project will try the Health App Recommendation Tool (HART) with family caregivers of people with Alzheimer's disease or related dementias to see if it helps them find and use helpful health apps.

Quick facts

Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment15 (estimated)
SponsorUniversity of Pittsburgh
Academic / other
Locations1 site (Pittsburgh, Pennsylvania)
StatusRecruiting
StartedDecember 5, 2025
Main results expectedSeptember 30, 2026
Study endsNovember 30, 2026
Registry record updatedOctober 8, 2026
Trial IDNCT07216716 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal participants are primary family caregivers aged 18–65 who live with and routinely care for a person with Alzheimer's disease or a related dementia and who own or have access to a smartphone, tablet, or smartwatch.

Probably not a fit

People with Alzheimer's disease or severe cognitive decline, part-time or secondary caregivers, and anyone without access to smart devices are unlikely to benefit from this pilot.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot will recruit 15 family caregivers who live with and routinely care for someone with Alzheimer's disease or a related dementia to test HART's acceptability and usability in real-world settings. HART collects brief information about needs, accessibility, supports, and technology skills, then uses a matching algorithm against a library of objectively reviewed health apps to generate personalized recommendations. Participants will trial recommended apps and provide structured feedback on fit, usability, and usefulness. The focus is on refining the tool and understanding how well it connects caregivers with appropriate digital resources rather than measuring clinical outcomes.

Why it matters

Potential benefit: If successful, HART could help caregivers quickly find usable, relevant health apps that support their wellbeing and caregiving tasks.

How similar studies have gone: App-recommendation and assistive-technology matching approaches have shown promise in other groups, but using a systematic tool like HART specifically for dementia caregivers is relatively novel, with preliminary HART evaluations showing encouraging results.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Aged between 18 and 65
* Serving as an active caregiver for a loved one with Alzheimer's disease or a related dementia
* Have access to smart devices such as smartphones, tablets, or smartwatches

Exclusion Criteria:

* Individuals with Alzheimer's disease or a related dementia, or with severe cognitive decline, will be excluded
* Participants who do not provide caregiving on a routine basis (e.g., part-time or secondary caregivers) will be excluded
* Participants who do not own or have access to any smart device will be excluded

Where it's running

  • University of Pittsburgh
    Pittsburgh, Pennsylvania, United States
    Recruiting

Study contacts

  • Principal investigator: Julie M Faieta, PhD, MOT — University of Pittsburgh
  • Study coordinator: Julie M Faieta, PhD, MOT
  • Email: juf52@pitt.edu
  • Phone: 412-648-7792

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.